578 results on '"Del-Bel, Elaine"'
Search Results
2. Novel Proline Transporter Inhibitor (LQFM215) Presents Antipsychotic Effect in Ketamine Model of Schizophrenia
3. Cannabidiol exerts antipyretic effects by downmodulating inflammatory mediators in LPS-induced fever
4. Anti-nociceptive effects of non-antibiotic derivatives of demeclocycline and doxycycline against formalin-induced pain stimulation
5. Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission
6. 4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms
7. Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors
8. Doxycycline inhibits dopaminergic neurodegeneration through upregulation of axonal and synaptic proteins
9. The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex
10. Doxycycline diminishes the rewarding and psychomotor effects induced by morphine and cocaine
11. Effects of hydrogen gas inhalation on L-DOPA-induced dyskinesia
12. Addressing the opportunity gap in the Latin American neuroscience community
13. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
14. Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
15. Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia
16. What Can We Learn from Animal Models to Study Schizophrenia?
17. Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556
18. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia
19. Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors
20. Cannabidiol improves non-motor symptoms, attenuates neuroinflammation, and favours hippocampal newborn neuronal maturation in a rat model of Parkinsonism.
21. Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation
22. Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels
23. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum
24. Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors
25. Astrocyte Intracellular Ca2+and TrkB Signaling in the Hippocampus Could Be Involved in the Beneficial Behavioral Effects of Antidepressant Treatment
26. In-tube solid-phase microextraction directly coupled to tandem mass spectrometry for anandamide and 2-arachidonoylglycerol determination in rat brain samples from an animal model of Parkinson's disease
27. Sodium nitroprusside enhances stepping test performance and increases medium spiny neurons responsiveness to cortical inputs in a rat model of Levodopa‐induced dyskinesias
28. Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia
29. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia
30. Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
31. Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia
32. The two synthetic cannabinoid compounds 4′‐F‐CBD and HU‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes.
33. The two synthetic cannabinoid compounds 4′‐F‐CBD and HU‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes
34. The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex
35. Extrapyramidal Side Effects with Chronic Atypical Antipsychotic Can Be Predicted by Labeling Pattern of FosB and phosphoThr34-DARPP-32 in Nucleus Accumbens
36. Contributors
37. Management with antibiotics in Parkinson's disease
38. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity
39. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
40. The role of striatum and prefrontal cortex in the prevention of amphetamine-induced schizophrenia-like effects mediated by nitric oxide compounds
41. Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury
42. The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases
43. CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
44. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity
45. Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions
46. Beneficial effects of benzodiazepine on masticatory muscle dysfunction induced by chronic stress and occlusal instability in an experimental animal study
47. Doxycycline to treat levodopa-induced dyskinesias in Parkinson’s disease: a preliminary study
48. Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
49. Effects of the monoamine stabilizer (−)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity
50. Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.